Predictive markers in the adjuvant therapy of non-small cell lung cancer

被引：25

作者：

Filipits, Martin ^{[1
]}

Pirker, Robert ^{[1
]}

机构：

[1] Med Univ Vienna, Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria

来源：

LUNG CANCER | 2011年 / 74卷 / 03期

关键词：

NSCLC; Adjuvant therapy; Targeted therapy; Customized therapy; Chemotherapy; Predictive biomarkers; EGFR inhibitors; III BETA-TUBULIN; DEPENDENT KINASE INHIBITOR; MESSENGER-RNA EXPRESSION; CISPLATIN PLUS GEMCITABINE; BIO POOLED ANALYSIS; PROGNOSTIC-FACTOR; RAS ONCOGENE; PHASE-III; MICRORNA EXPRESSION; TARGETED THERAPIES;

D O I：

10.1016/j.lungcan.2011.06.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adjuvant chemotherapy increases the 5-year survival rate of patients with completely resected non-small cell lung cancer (NSCLC) by absolute 5%. Molecular-targeted therapies and predictive biomarkers to select those patients who benefit hold promise to further improve the outcome. Several biomarkers including ERCC1, BRCA1, EGFR, or gene signatures have been characterized in retrospective analyses of adjuvant therapy trials. However, differences in trial design and laboratory tests might have affected the outcome and might explain discordant results. With regard to many biomarkers, laboratory tests for their assessment remain to be standardized. After standardization of these tests and further validation studies, biomarkers might allow individualizing adjuvant treatment in patients with completely resected NSCLC in the future. (C) 2011 Published by Elsevier Ireland Ltd.

引用

页码：355 / 363

页数：9

共 50 条

[1] Adjuvant therapy for non-small cell lung cancer
Franca, Leticia Barbosa
Oliveira, Marcia Aparecida
Small, Isabele Avila
Zukin, Mauro
de Lima Araujo, Luiz Henrique
[J]. JORNAL BRASILEIRO DE PNEUMOLOGIA, 2011, 37 (03) : 354 - 359
[2] Adjuvant therapy in non-small cell lung cancer
Rusch, Valerie W.
[J]. ANNALS OF THORACIC SURGERY, 2007, 84 (05): : 1793 - 1794
[3] Predictive molecular markers in non-small cell lung cancer
Rosell, R
Tarón, M
O'Brate, A
[J]. CURRENT OPINION IN ONCOLOGY, 2001, 13 (02) : 101 - 109
[4] Neoadjuvant and adjuvant therapy of non-small cell lung cancer
Rajdev, L
Keller, SM
[J]. SURGICAL ONCOLOGY-OXFORD, 2002, 11 (04): : 243 - 253
[5] ADJUVANT THERAPY FOR NON-SMALL CELL LUNG-CANCER
EVANS, WK
[J]. CHEST, 1989, 96 (01) : S87 - S91
[6] Adjuvant and neoadjuvant therapy in non-small cell lung cancer
Belani, CP
[J]. SEMINARS IN ONCOLOGY, 2005, 32 (02) : S9 - S15
[7] Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer
Chuang, Jody C.
Liang, Ying
Wakelee, Heather A.
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 31 - +
[8] MIB-1 labeling index is useful as prognostic and predictive markers for adjuvant therapy in non-small cell lung cancer
Yanagawa, N.
Osakabe, M.
Ogata, S-Y.
Shiono, S.
[J]. ANNALS OF ONCOLOGY, 2015, 26 : 12 - 13
[9] Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients
Gadgeel, Shirish M.
Bepler, Gerold
[J]. FUTURE ONCOLOGY, 2013, 9 (12) : 1909 - 1921
[10] Vaccines as adjuvant therapy for non-small cell lung cancer (NSCLC)
Butts, Charles
[J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S220 - S221

← 1 2 3 4 5 →